Nonsteroidal selective androgen receptor modulator Ostarine() in cancer cachexia. Future oncology (London, England) [Future Oncol] Journal article | | Title | Nonsteroidal selective androgen receptor modulator Ostarine() in cancer cachexia. | | Author(s) | Zilbermint MF, Dobs AS | | Institution | Department of Medicine, Saint Agnes Hospital, 900 South Caton Avenue, Box 198, Baltimore, MD 21229, USA. | | Source | Future Oncol 2009 Oct; 5(8):1211-20. | | Abstract | Cancer cachexia is a complex syndrome, affecting up to 60% of the approximately 1.4 million patients diagnosed with cancer each year in the USA. This condition is characterized by progressive deterioration of a patient's nutritional status, weight loss, anorexia, diminished quality of life and increased mortality and morbidity. Current therapy with progestational, anti-inflammatory and anabolic agents is often ineffective and has a large number of undesirable effects. The newly developed nonsteroidal selective androgen receptor modulator Ostarine() has demonstrated promising results in Phase I and II clinical trials, increasing total lean body mass, enhancing functional performance and decreasing total tissue percent fat. This selective androgen receptor modulator may have the ability to perform as a potent anabolic agent with minimal side effects on other organs (prostate and hair follicles), thus presenting a new strategy in managing cancer cachexia. However, more extensive data is required before its efficacy is confirmed. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19852734 |
|
|
| |
Advertise on this site.
| | |
|
